← boardnext 2026-09
TLSA
Tiziana Life Sciences LTDdistress 6/10 · elevated risk$0.95+0%today-62% from 52w high
Neurology 1
Lead: Multiple System Atrophy
Revenue
pre-revenue
Liquidity
$6M
Runway
0.5 yrs
Shares 1y
0%
Price & events
-42.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-13.6%
1W
-18.1%
1M
-22.8%
3M
-41.7%
6M
-46.6%
1Y
+5.6%
2Y
-54.1%
5Y
-63.2%
All
Overview
- Market Cap
- $114.49M
- Volume
- 32.63K
- 52 Week Range
- $0.95 – $2.50
- Total Shares
- 120.51M
- Float Shares
- 63.89M
- Short %
- 4.31%
- % Held by Insiders
- 47.65%
- % Held by Institutions
- 2.94%
- RVOL
- 0.14x
- Beta
- 0.44
Pipeline stages · 1 programs
Foralumab Nasal
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Foralumab | Secondary Progressive Multiple Sclerosis | — | active not recruiting |
| 2027-04-01 Estimated 50% readout ~2027-05-16 | Phase 2 | Foralumab Nasal | Multiple System Atrophy | — | recruiting |
| 2026-04-30 | Phase 2 | Foralumab TZLS-401 100 µg | Non-Active Secondary Progressive Multiple Sclerosis | 55 | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+857% upside) · 1 analysts
- no recent rating changes
Competitors — Multiple System Atrophy
Recent news
- 2026-07-22Tiziana Life Sciences (TLSA) Executive Chairman Increases Stake - GuruFocus
- 2026-07-22Tiziana Life Sciences Chairman Boosts Stake to Nearly 35% in July Share Purchase - TipRanks
- 2026-07-22Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman - The Manila Times
- 2026-07-22Tiziana Life Sciences (Nasdaq: TLSA) chair lifts holding to 34.93% stake - Stock Titan
- 2026-07-22Tiziana Life Sciences says executive chairman increased stake with share purchase - Proactive financial news
- 2026-07-07Price to sales forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
- 2026-06-25Tiziana Life Sciences Ltd. - Via Ritzau
- 2026-06-25Tiziana (Nasdaq: TLSA) completes enrollment in Phase 2a INFORM-MS study - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.